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Abstract: Malignant pleural mesothelioma (MPM) is a tumour related to a historical exposure to asbestos 
fibres. Currently, the definite diagnosis is made only by the histological examination of a biopsy obtained 
through an invasive thoracoscopy. However, diagnosis is made too late for curative treatment because of 
non-specific symptoms mainly appearing at advanced stage disease. Hence, due to its biologic aggressiveness 
and the late diagnosis, survival rate is low and the patients’ outcome poor. In addition, radiological imaging, 
like computed tomographic scans, and blood biomarkers are found not to be sensitive enough to be used 
as an early diagnostic tool. Detection in an early stage is assumed to improve the patients’ outcome but 
is hampered due to non-specific and late symptomology. Hence, there is a need for a new screening and 
diagnostic test which could improve the patients’ outcome. Despite extensive research has focused on 
blood biomarkers, not a single has been shown clinically useful, and therefore research recently shifted 
to “breathomics” techniques to recognize specific volatile organic compounds (VOCs) in the breath of 
the patient as potential non-invasive biomarkers for disease. In this review, we summarize the acquired 
knowledge about using breath analysis for diagnosing and monitoring MPM and asbestos-related disorders 
(ARD). Gas chromatography-mass spectrometry (GC-MS), the gold standard of breath analysis, appears 
to be the method with the highest accuracy (97%) to differentiate MPM patients from at risk asbestos-
exposed subjects. There have already been found some interesting biomarkers that are significantly elevated 
in asbestosis (NO, 8-isoprostane, leukotriene B4, α-Pinene…) and MPM (cyclohexane) patients. Regrettably, 
the different techniques and the plethora of studies suffer some limitations. Most studies are pilot studies 
with the inclusion of a limited number of patients. Nevertheless, given the promising results and easy 
sampling methods, we can conclude that breath analysis may become a useful tool in the future to screen for 
MPM, but further research is warranted. 
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Introduction
Asbestos
Asbestos fibres are fibrous silicate minerals, widely used 
in construction during the 20th century due to its strong 
fire, chemical and abrasion resistance (1,2). Asbestos is a 
collective name for different fibre groups characterized 
by specific features: a serpentine (chrysotile) and 5 
amphiboles (crocidolite, amosite, anthophyllite, actinolite 
and tremolite) (1,2). Asbestos fibres cause cancer of the 
lung, larynx, ovaries and mesothelium (mesothelioma), as 
well as benign disease like asbestosis, pleural plaques and 
thickening and effusion in the pleura (3). Approximately 
95% of all globally used asbestos products are chrysotile. 
Nevertheless, although chrysotile fibres are thought to be 
less carcinogenic, all asbestos fibres have been shown to be 
carcinogenic and are classified a group 1 human carcinogen 
by the International Agency for Research on Cancer (IARC) 
of the World Health Organization (WHO) (1,2,4).
Asbestos-related diseases (ARD)
Asbestos can cause benign ARD, like asbestosis and pleural 
plaques. Asbestosis is identified as bilateral disseminated 
interstitial fibrosis of the lungs, but not of the pleura (5). 
The presence of this disease indicates a heavy previous 
exposure to asbestos fibres. Unlike for mesothelioma, there 
is a safe exposure threshold of 25–100 fibres/mL/year, 
under which asbestosis does not occur (6). The median 
latency period is 31 years, depending on the intensity of the 
exposure. The more intense the exposure, the more likely 
asbestosis will occur (7,8). Pleural plaques are the most 
common manifestation of asbestos exposure (9). Plaques are 
small areas of hyaline fibrosis which can become calcified 
and mostly originate on the parietal pleura of the chest wall 
and diaphragm (10). Because of the layers of hyalinised 
collagen fibres, plaques appear white and are often multiple 
and bilateral (11,12). Plaques occur with lower inhaled 
asbestos burdens and can result from small temporally 
exposures. Plaques appear 20–30 years after exposure in 
50–60% of individuals with a heavy or prolonged asbestos 
exposure and serve as a marker of asbestos exposure (9,11).
Malignant pleural mesothelioma (MPM) is a rare, 
aggressive and treatment-resistant tumour originating 
from the serosal cells lining the lungs (13). MPM has a 
median latency time of 40–50 years between first exposure 
to asbestos fibres and its diagnosis (14). There is a proven 
link between an increased exposure to asbestos and the 
development of MPM (15). However, there is no safe 
threshold where under MPM will not develop. A single, 
intensive exposure is therefore enough to induce MPM (5). 
The incidence rates of MPM worldwide are highest in 
the United Kingdom, Australia, The Netherlands, New 
Zealand, Malta and Belgium, where the incidence ratio 
is at least 2 per 100,000 capita (16). In 2015, 301 people 
have been diagnosed with MPM in Belgium of which 238 
were male (17,18). According to the WHO, mesothelioma, 
asbestos-related lung cancer and asbestosis globally cause 
107,000 deaths annually. In 2005, occupational asbestos 
exposure was estimated to cause 43,000 deaths worldwide 
due to MPM and 7,000 deaths due to asbestosis (19). Given 
to the long interval between the first causative asbestos 
exposure and the diagnosis, the incidence rate of MPM is 
expected to rise in the next decades (20).
Patients experience non-specific symptoms, like 
dyspnoea and thoracic pain (21), that contribute to delaying 
diagnosis to advanced stage disease in mostly elderly 
persons with a median age at diagnosis of 65 years (22). 
MPM has a very high mortality rate (12). After diagnosis is 
made, untreated patients have a median survival of about 9 
months which can be increased to 12 months with standard-
of-care chemotherapy (23). This is an alarming fact and it is 
assumed that an early diagnosis could possibly contribute to 
improve this low survival rate, as seen for lung cancer (24).
There is no curative treatment and treatment is 
limited to palliative chemotherapy. Patients with a good 
performance benefit from this treatment with an increased 
survival of around two months and an improvement of 
symptoms like pain and shortness of breath (25). The 
standard-of-care chemotherapy consists of the combination 
of an antifolate (pemetrexed) and a platinum-derivate 
(cisplatin) (26). However, the addition of bevacizumab 
(angiogenesis inhibitor) to the standard-of-care recently 
showed to increase the median overall survival of patients 
to 18 months (27). The upcoming field of immunotherapy 
as experimental treatment for mesothelioma furthermore 
holds promise for future improvement on survival by MPM 
treatment (28,29). The added value of these new treatment 
options should be further investigated in order to become 
the new standard-of-care (26,27,30,31).
Pathophysiology
Inhaling asbestos fibres causes chronic inflammation and 
oxidative stress. First, chronic inflammation is caused by 
the extended phagocytic activity of macrophages engulfing 
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asbestos fibres, called frustrated phagocytosis. This induces 
fibrosis, thereby generating reactive oxygen species (ROS), 
resulting in asbestosis (8). However, this fibrosis can also be 
malignant. Therefore, people suffering from asbestosis have 
an increased risk for developing MPM and lung cancer (32). 
Second, the asbestos fibres have a high iron content 
that triggers Fenton-like chemical reactions, leading to 
constantly maintaining the induction of ROS (33), leading 
to cellular and DNA damage. MPM is usually classified into 
three subtypes according to histology: biphasic, sarcomatoid 
and epithelioid (10). Epithelioid MPM is the most common 
subtype and these patients have a better overall survival 
in comparison with patients who suffer from other MPM 
subtypes (34).
Diagnosis of asbestos-related diseases
The diagnosis of asbestosis is mainly made non-invasively 
based upon clinical and radiological grounds. It is therefore 
mandatory to document previous asbestos exposure 
whereafter a physical examination can determine interstitial 
fibrosis by hearing crackles on auscultation of the lungs. 
Further diffuse opacities are detectable on radiologic 
examination. At last, a lung function test will indicate 
impairment. Analysis of a biopsy is rarely required (35). 
Currently, imaging tests can suggest the presence of 
MPM after a thorough anamneses. Usually, a unilateral 
pleural effusion is seen on chest X-ray. The sensitivity for 
detecting MPM with a chest X-ray depends on the location, 
shape, size and calcification of the tumour and the technical 
quality of the X-ray. For this reason, it is less sensitive 
for detecting pleural diseases (especially pleural plaques) 
than a chest CT-scan, which is the gold standard for the 
evaluation and the follow-up of MPM (11). However, only 
a histopathological examination of a biopsy obtained after 
an invasive thoracoscopy allows to make a definitive MPM 
diagnosis (33). Consequently, non-invasive biomarkers that 
may contribute to an earlier diagnosis are of great interest.
Blood biomarkers
Blood has been studied to look for biomarkers for MPM and 
has been reviewed previously (33). One of the most studied 
biomarkers is serum mesothelin-related protein (SMRP). 
Mesothelin is a surface protein which plays a role in 
mesothelial cell adhesion and becomes the circulating blood 
product SMRP after cleavage. In 60% of MPM patients, 
an elevation of SMRP was seen (25,36). However, despite a 
high specificity, SMRP lacks sensitivity. Therefore, further 
research focused on the combination of SMRP with other 
biomarkers in order to improve the diagnostic accuracy 
for early diagnosis of MPM (37). Moreover, the histology 
is an important determinant of prognosis of MPM. Some 
studies found an inverse relation between SMRP and 
overall survival, but the prognostic impact on overall 
survival was lost when limited to epithelial MPM (38). 
Furthermore, MPM patients with recurrence or progression 
after initial treatment had the highest values of SMRP. As 
a result, SMRP concentrations could be used as a tool for 
monitoring patient’s response to treatment (39). 
Other research focused on serum and plasma osteopontin 
(OPN) as second important biomarker (40). SMRP and 
OPN are both promising biomarkers for diagnosis of 
MPM (41), but the specific diagnostic accuracy remains 
insufficient, restricting the use of these compounds in 
clinical practice (40,42). Other blood biomarkers are also 
potentially useful: fibulin-3, high mobility group box 1 
(HMGB1), aptamers [SOMAmer (Slow Off-rate Modified 
Aptamer)] and micro-RNA’s (38). In some studies, higher 
plasma fibulin-3 levels were found in MPM patients than 
in control groups (43). Hyperacetylated HMGB1 could 
have a role as a potential diagnostic marker to differentiate 
MPM patients form asbestos-exposed individuals and 
healthy controls (HC) (38,44). Finally, using SOMAmers as 
capture agents, MPM was detected in a group of asbestos-
exposed persons with 92% accuracy, and its sensitivity was 
found associated with pathological stage (38). These results 
provide a probable use for early diagnosis of MPM in a high 
risk population. Although some of the abovementioned 
biomarkers show diagnostic potential, none of these are 
validated and therefore are not currently implemented 
in clinical practice to screen potential individuals at risk 
for MPM. This urges the need to continue the search 
for accurate biomarker to enable an early stage diagnosis 




Exhaled breath contains a liquid phase (water vapor) 
and a gaseous phase including nitrogen, oxygen, carbon 
dioxide, inert gases, and a small function of volatile organic 
compounds (VOCs) (45). VOCs are lipophilic components 
with low molecular weight (<300 Da) and have a high vapor 
pressure at a temperature of approximately 20 ℃ (46). They 
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are released from the human body and can be detected 
through urine, skin, blood and exhaled breath (47). In a 
typical population, a single breath sample contains around 
200 different VOCs, mostly at picomolar range. In total, 
more than 3,000 different VOCs are already described (45). 
Besides organic compounds, breath can contain inorganic 
compounds, such as NO (48). 
The liquid phase encloses exhaled breath condensate 
(EBC) and aerosols (49), containing different diluted non-
volatile molecules ranging from simple ions to DNA, 
leukotrienes, C-reactive protein, lipid, microbiota, etc. 
Hence, for analyzing these biomarkers, EBC is the best 
approach (50). 
Origin of VOCs
VOCs can originate from exogenous sources via inhalation 
and skin adsorption, but, more importantly, can also arise 
from the physiological and pathophysiological processes 
in the body, such as inflammation, oxidative stress and fat 
metabolism (51). Endogenously formed VOCs enter the 
bloodstream and are transported to the lungs. Through the 
gas exchange mechanisms in the lung alveoli, VOCs are 
released in the breath (52). Hence, the composition and 
concentration of breath VOCs can be used as easy, non-
invasive biomarkers that reflect the metabolic changes and 
pathologic processes throughout the body.
VOCs as biomarkers for disease
As with blood biomarkers, a single breath compound is 
expected to be insufficient to obtain enough information 
about environmental exposure or chronic diseases, due 
to the complex underlying pathophysiological processes 
of disease. This urges to explore the total amount of 
exhaled VOCs, thereby focussing on biomarker panels, 
and allowing a subsequent identification and enrichment 
of VOCs of interest. In that way, a unique VOC pattern 
can be generated, which has shown to be promising to 
detect infectious diseases (pneumonia, H. pylori infection), 
cancer (prostate cancer, colorectal cancer,…), pulmonary 
diseases (asthma, chronic obstructive pulmonary disease), 
cardiovascular diseases, gastro-intestinal diseases (gastric 
carcinoma, gastric ulcer, gastritis) and liver diseases (53-61). 
This is of particular interest because the abovementioned 
diseases relate to various metabolic processes in the body. 
Since patients can have comorbidities, collecting the 
plethora of VOCs can allow to find information about 
comorbidities next to the disease of interest (47).
The pathogenesis of a human tumour is a multistep 
process in which cancer cells acquire several biological 
characteristics, called hallmarks of cancer, that allow a 
normal cell to become malignant. These include proliferative 
signalling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis 
and activating invasion and metastasis (62). Inflammatory 
cells foster these hallmarks and therefore promote tumour 
development (62). This changes cell metabolism and, hence, 
a change in VOC production is to be expected. Furthermore, 
oxidative stress is a vital risk factor for the development of 
cancer (47). Since inflammation is a hallmark of cancer, 
excessive ROS production occurs due to lipid peroxidation 
and induction of cytochrome P450 enzymes, and thereby 
influencing VOCs. Above of this, many metabolic pathways 
change the VOC production in the body because they are 
(over)activated in the occurrence of cancer. Hydrocarbons 
(alkanes, alkenes), alcohols, aldehydes, ketones, esters, nitriles 
and aromatic compounds are found to be cancer-related 
VOCs, but they can also be related to other inflammatory 
processes or be induced by other sources, such as tobacco 
smoking (47), thereby limiting their use as stand-alone 
markers in favour of more informative biomarker panels. 
Since asbestos fibres induce chronic inflammation 
and oxidative stress that leads to MPM, this will result in 
raising the cell’s metabolic activity and the production of 
ROS. This will ultimately lead to a change in the VOC 
production and proposes that VOCs can be used as non-
invasive diagnostic biomarkers for disease. Given the ease 
and non-invasiveness of sampling, this systematic review 
will therefore survey the existing knowledge of how to use 
volatile biomarkers in breath for the management of MPM 
and asbestosis. 
Breath analysis: methods
Because the current diagnostic work-up of MPM and many 
other cancers suffers from limitations like long latency or 
invasiveness, there is need for a new test that is fast and 
non-invasive. Hence, in contrast to current diagnostic 
methods, breath analyzing techniques are promising where 
only a breath sample is needed. Given this non-invasive 
and practical sampling, research has recently led to the 
rise of a high-throughput breathomics era, using different 
techniques to analyse VOCs in breath, all having their 
benefits and limitations (Table 1). 
The f irst  technique,  gas chromatography-mass 
spectrometry (GC-MS), is the gold standard in breath 
analysis. This offline method makes it possible to separate, 
quantify and identify the individual compounds of a gaseous 
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mix (46). The breath is collected into bags or onto fibres 
[solid-phase micro-extraction (SPME) fibres] or thermal 
desorption tubes where VOCs are concentrated (33). The 
VOCs are desorbed and separated over a heated GC-
column based upon their chemical characteristics (51). 
Afterwards, the VOCs are ionised and fragmented in the 
MS, allowing to identify and quantify the VOCs. Despite 
the fact that GC-MS allows quantitative analysis, it is time-
consuming, immobile, costly and there is a need of an 
trained expert operator (33). 
Next to this, there are handheld electronic noses (eNoses). 
This sensor technology allows to recognize the bulk of 
VOCs as a breath pattern or ‘smellprint’ and is based upon 
human olfactory perception. Hence, eNoses allow bedside 
sampling and fast analysis but do not allow specific VOC 
identification. 
Another technique to analyse VOCs is ion mobility 
spectrometry (IMS). With this online method, the patient 
breathes directly into the IMS device. The velocity of 
the VOCs to traverse a drift tube under influence of an 
electrical field and a counter gas is measured, and will relate 
to the VOCs’ size, charge, shape and mass (the so-called ion 
mobility). This allows the separation of compounds (33) and 
individual VOC identification becomes possible due to the 
coupling with a multi-capillary column (MCC) (51). This 
technique combines the advantages of GC-MS and eNose 
sampling by allowing a fast and low cost analysis, sampling 
at the patients’ bedside and the identification of compounds.
Canine scent, is based on the capacity of dogs to smell 
and discriminate between different breath samples. It is 
relatively expensive and there is no VOC quantification 
or identification possible (51). Furthermore, selected ion 
flow tube-mass spectrometry (SIFT-MS), allows one to 
quantify a range of VOCs in air and breath in a single 
test. This technique is based on the principle of chemical 
ionization (63) and potentially allows for a fast assessment 
of occupational exposure in real time (64,65). The main 
limitation is the uncertain quantification and identification 
of analyte ions, and the fact that it is expensive and space-
consuming (63,65). Lastly, proton transfer reaction-mass 
spectrometry (PTR-MS) is also based on the principal of 
chemical ionization whereby analytes are characterized 
according to mass/charge ratio. It is accurate, quick, less 
time consuming, ideal for complex gas mixtures and can 
be used as an online breath analyzing technique (63). The 
downside is that identification of compounds is not possible, 
and that it is also space-consuming and expensive (63).
Goals of the systematic review 
Because the current methods for diagnosing MPM hamper 
an efficient diagnosis and curative treatment (late diagnosis, 
expensive and/or invasive procedures), there is a strong need 
for a non-invasive tool which may allow earlier diagnosis. 
Hence, given that blood biomarkers have not proven to be 
useful for early detection of surviving, and breath analysis 
is a new, innovative field of research, we want to explore 
the current knowledge of using breath analysis for the 
management and diagnosis of MPM and asbestosis. Our 
findings are summarized in this systematic review according 
to the recommendations of the Cochrane Collaboration for 
diagnostic research.
Table 1 Overview of the benefits and limitations of the different breath analyzing techniques for VOCs
Characteristic GC-MS IMS eNose Canines SIFT-MS PTR-MS
Sensitivity +++ ++ +/− −−/++ ++ +
Real-time? No Yes No Yes Yes Yes
Sampling Offline Online Offline Online Online/offline Online/offline












Time Slow, time-consuming Fast, easy Fast, easy Fast, easy Fast, easy Fast, easy
Price +++ + + ++ +++ +++
Transportable? No Yes Yes Yes No No
VOC identification? Yes Pseudo No No No No
+, medium; ++, high; +++, very high; −, low; −−, very low.  eNose, Electronic nose; GC-MS, gas chromatography-mass spectrometry; IMS, ion mobility 
spectrometry; MCC, multi-capillary column; PTR-MS, proton transfer reaction-mass spectrometry; SIFT-MS, selected ion flow tube-mass spectrometry; VOC, 
volatile organic compound.
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Materials and methods
Search strategy
We searched for studies concerning subjects with MPM or 
asbestosis compared to HC or asymptomatic asbestos-exposed 
(AEx) subjects. We looked for studies using breath analysis as 
a diagnostic, monitoring and/or prognostic tool comparing 
the efficacy with the histopathological examination of a biopsy 
specimen. We also searched the literature for significantly 
higher breath levels of VOCs, inorganic compounds and 
fractions of EBC in subjects with MPM and/or asbestosis to 
differentiate them from healthy (asbestos-exposed) controls, 
since these non-invasive biomarkers could be used to screen 
these at-risk groups for MPM. 
The databases MEDLINE (PubMed Database) and Web 
of Science were consulted from September 26, 2017 till 
March 7, 2018. The following combination of terms was 
used in both databases: (mesothelioma OR asbestosis OR pleural 
plaques OR asbestos) AND (breath analysis OR breath test 
OR volatile organic compounds OR exhaled breath OR exhaled 
breath condensate). The selection procedure of articles for 
systematic review is shown in Figure 1. 
In- and exclusion criteria
Using this search strategy, 204 articles were identified. First, 
duplicates from both databases were removed. Second, the 
titles and abstracts of the remaining articles were assessed by 
four independent reviewers (J Vandersnickt, C Millevert, L 
Arnouts and L Brusselmans) and the outcome compared. If 
there were disagreements, it was discussed until consensus. We 
excluded 127 articles based on their title or abstract, and from 
the 23 remaining articles the full text was read independently 
by the reviewers. Afterwards, 11 more articles were excluded: 
3 had no relevant outcomes and 8 were congress abstracts. 
Ultimately, 12 articles remained for discussion.
Publication date was not an exclusion criterion, since 
breath analysis related to this topic is a recent research 
field (the oldest article dates from 2006). Furthermore, 
there was no language bias since the keywords we entered 
into the databases only yielded articles written in English. 
Reviews were excluded and only primary studies included, 
focusing on breath analysis as a diagnostic/screening tool 
and dealing with the pathologies of MPM or benign ARD, 
like asbestosis. Furthermore, we only included articles 
on pleural mesothelioma, and other forms as pericardial, 
peritoneal and tunica vaginalis mesothelioma were 
excluded. In addition, articles describing breath analysis as a 
diagnostic tool for other cancers or diseases were excluded. 
Because the limited research currently available on these 
topics, we did not screen on age, smoking behaviour or 






Records excluded based on 
title and abstract
(n=127)
Full-text articles screened 
for eligibility
(n=23)
Full-text articles excluded with 
reasons  (n=11)
No relevant outcomes (n=3)
Congress abstracts (n=8)
Studies included in 
qualitative analysis
(n=12)
Records identified through 
searching in PubMed 
(n=100)
Records identified through 
searching in Web of Science
(n=104)
Figure 1 Flowchart.
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Data collection and analysis
The qualitative and quantitative characteristics of the 
included articles were independently extracted by four 
reviewers according to the recommendations of the 
Cochrane Collaboration for diagnostic research (66). 
Results and discussion
Twelve relevant studies concerning breath analysis as a 
diagnostic or screening tool for ARD were included. Table 2 
summarizes specific exclusion criteria for the selection 
of groups together with the different characteristics and 
the results of the individual studies. In general, the HC 
included in all the studies, were never occupationally 
exposed to asbestos, and the research groups used different 
analyzing instruments, in- and exclusion criteria and patient 
and control groups. Also the sample size of the studies 
fluctuates. Because of this heterogeneity, it was not possible 
to yet run a meta-analysis. 
Promising results were found comparing the different 
diagnostic tools to distinguish patient and control groups. 
When looking at the possibility to discriminate HC and 
MPM patients based upon VOCs, the lowest accuracy was 
found using MCC-IMS (65%) (31). In contrast, the highest 
accuracy (95%) was seen using an eNose (73). GC-MS 
generated intermediate results with an accuracy of 71% (75). 
Despite the possibility to distinguish MPM patients from 
HC controls, it is of less clinical importance given that HC 
persons are not the at-risk groups of interest for screening. 
More important is thus to look for markers for asbestos 
exposure by comparing HC with AEx or ARD persons and 
to look for biomarkers of MPM after asbestos exposure, 
comparing AEx and/or ARD persons with MPM patients. 
We found three qualitative studies from the same research 
group that directly compared HC with AEx subjects in order 
to identify volatile markers for asbestos-exposure (31,52,75). 
Using MCC-IMS, these groups could be distinguished with 
61–91% accuracy (52,75). Using GC-MS or eNose, the 
accuracy was respectively 71% and 65% (31).
Since asymptomatic AEx persons and persons with ARD 
are at the highest risk of developing MPM, these are the 
groups of interest where a breath test could be used as 
screening tool. When discriminating MPM patients from 
AEx subjects, the eNose showed an accuracy ranging from 
73% to 81% (74,75), while GC-MS could separate these 
groups with an accuracy of 97% (31) and MCC-IMS with 
an accuracy of 88% (52,75). When distinguishing MPM 
patients from subjects with ARD, the studies yielded an 
accuracy of 70% using the eNose, 82% using MCC-IMS 
and 79% using GC-MS (31,75). Furthermore, if both AEx 
and ARD groups are pooled into one asbestos-exposed 
group and tried to be discriminated from MPM patients, 
we find once more the lowest accuracy with eNose (74%) 
and the highest with GC-MS (94%) (31,75). MCC-IMS 
analysis discriminated these groups with 85% accuracy (75). 
This could be explained by the fact that eNoses recognize a 
pattern of VOCs and do not identify VOCs, in contrast to 
GC-MS or MCC-IMS, which can focus on specific VOCs. 
With GC-MS, de Gennaro et al. found cyclopentane as a 
marker for long-term asbestos exposure and cyclohexane 
to be the only compound that distinguished MPM patients 
from former asbestos workers and HC (72). The latter 
compound was also found by Lamote et al. to distinguish 
MPM patients from AEx subjects (31), underlining its 
potential importance to be used as screening biomarker in 
AEx subjects. Nevertheless, cyclohexane is also identified 
in animal models with pneumonia (76) and in the breath 
of lung cancer patients (51). This suggests the VOC is 
generated by oxidative stress in inflamed tissue and serves 
as non-specific marker for inflammation, which further 
explains the lack of specificity for MPM (51). Despite the 
limited amount of studies, it is remarkable that de Gennaro 
et al. (72) and Lamote et al. (31) obtained overlapping 
results regarding VOCs, like cyclopentane, cyclohexane and 
limonene when using GC-MS. Despite GC-MS being an 
expensive and time-consuming technique, building targeted 
sensors sensitive for these specific identified compounds 
might be a future step in the development of a handheld 
screening tool. 
Next to studies focussing on volatile biomarkers in 
breath, we also included articles looking at markers in 
EBC and inorganic compounds in breath (68). Levels of 
8-isoprostane were found significantly higher in patients 
with asbestosis, in AEx subjects and in AEx subjects 
with borderline parenchymal changes compared to HC 
(P=0.0001–0.0480) (32,67,68,70). In addition, alveolar 
NO, was significantly higher in patients with asbestosis 
and in AEx subjects with borderline parenchymal changes 
in comparison to HC (P=0.006–0.009) (67,68,70,71). 
This was also the case with levels of C-reactive protein, 
interleukine-6 and myeloperoxidase (74). Moreover, 
leukotriene B4 was the only biomarker that was significantly 
higher in AEx subjects with normal parenchymal changes 
compared to HC (P≤0.001) (70). 
Furthermore, the levels 8-iso-PGF2α, o-Tyr and 
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8-OHdG were significantly higher in subjects with asbestosis 
or silicosis in contrast with HC (P=0.01–0.05) (69). 
Lastly, Chow et al. found that hydrogen peroxide was 
significantly higher in patients with asbestosis in comparison 
with HC (P≤0.05) (68). Despite important findings, the 
abovementioned biomarkers measure chronic inflammation, 
and, therefore, are not specific for ARD or MPM. This is 
also true for alveolar NO, since this compound is also raised 
in patients with asthma or COPD (67), and for that reason, 
patients with asthma or COPD were excluded in several 
studies (67,68,70). Besides NO, also levels of leukotriene 
B4, produced by activated neutrophils, were found increased 
in patients with asthma and COPD (67). However, their use 
to detect MPM is not yet investigated and holds promise 
for further research.
Diagnostic tools
Three studies used an eNose as a diagnostic tool. This 
tool recognizes the bulk of the breath (52,73,75) but does 
not identify the specific VOCs that are responsible for 
any difference in exhaled breath patterns. This is reflected 
by lower discriminating characteristics due to a lower 
specificity, so more investigation is needed to gain more 
insight and to improve the methodology in the future (73). 
Nevertheless, it is a very promising and easy to use screening 
tool, and its discriminating capacity can be increased if 
specific VOCs of interest can first be identified where after 
specific orientated sensors can be developed. The group 
of Lamote et al. is the only one using MCC-IMS as a 
diagnostic tool, generating clinically relevant results. This 
is user-friendly, mobile and has low cost with the ability to 
identify compounds (52,75). A final analyzing technique, 
GC-MS, is the gold standard of breath tests. It has the 
highest sensitivity and allows the best identification of 
compounds, but is very expensive and time-consuming (31). 
It must be remarked that other promising techniques as 
SIFT-MS or PTR-MS have not yet been used to investigate 
their role as tools for MPM.
However, the choice of type of instrument used for 
breath analysis depends on the characteristics of the disease 
of interest and the intended use of the breath test. If using 
a breath test as screening tool for a rare disease as MPM, 
in a large at risk group such as AEx or ARD subjects, it is 
first important that the analysis technique yields a high 
sensitivity (75). In that way, breath tests will have very few 
false negatives and will have a high chance of detecting a 
rare disease if disease is present. Secondly, when screening a 
large at-risk target group for a rare disease, these screening 
tools should have a high negative predictive value (NPV). 
In that case, a negative test result reflects a very high 
change that disease is truly absent. This combination of a 
high sensitivity and NPV allows for an exclusive screening, 
whereby the large NPV rules out disease in the large 
number of screenees, and the high sensitivity will detect the 
rare disease like MPM when present. In this way, detection 
of MPM could be optimized, not subjecting every AEx 
person to a CT-scan, making diagnostic work-up more 
cost-effective. Considering a maximal sensitivity and NPV, 
Lamote et al. obtained results with high sensitivity (87–94% 
with MCC-IMS, 75–82% with eNose and 79–100% 
with GC-MS) and high NPV (83–96% with MCC-IMS, 
54–70% with eNose and 80–100% with GC-MS) when 
specifically discriminating MPM patients from at risk  AEx, 
ARD of combined subjects (31,75). These results underline 
the capacity of breath analysis as screening tool for subjects 
at risk for MPM allowing us to rule out MPM (31,75).
In summary, depending on the population, the best 
discriminative results are obtained with MCC-IMS or 
GC-MS. In MPM patients versus ARD subjects and 
MPM patients versus HC, we can see that the values of 
the accuracy are the highest in the studies that use MCC-
IMS as method (75). In contrast, GC-MS gives the best 
results with the comparison of MPM patients versus at 
risk AEx subjects and MPM patients versus AEx and ARD 
subjects. In the latter groups, Lamote et al. demonstrated 
a sensitivity and NPV of 100% (31). Given the high cost 
and analyzing time of these instruments, it is important 
to combine specific sensors against compounds of interest 
into a handheld eNose device in order to reduce sampling 
time and cost while maintaining the optimal screening 
characteristics.
Confounders
Although breath analysis is promising considering 
acceptable clinically relevant outcome and sampling 
advantages, there are some limitations to take into account 
for the detection of MPM and/or asbestosis. First of all, 
despite there is no correlation between the degree of 
asbestos exposure and pleural and parenchymal changes 
that can be seen on high resolution CT (70), the type 
of ARD and a wider range of asbestos disorders seem 
to affect exhaled breath biomarkers (73). Secondly, we 
cannot rule out or correct for the background asbestos 
exposure, which is also present in HC. Thirdly, VOCs 
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can also be exogenous. Hence, there is a possibility of 
environmental background contamination and that the 
VOCs found in research are not disease-specific but reflect 
environmental changes (73). Therefore, correction for 
background contamination is advisable. Despite the fact 
that some studies took background samples and corrected 
for this (31,52,72,75), most studies did not, and the effect of 
background contamination needs to be further investigated. 
Also, smoking can be a confounding factor that influences 
the VOC composition. Therefore, some studies matched 
the included subjects for smoking status (73). However, 
smoking is not as important as it would be for the diagnosis 
of lung cancer, because MPM development is not related 
to a previous smoking behaviour (73). This is strengthened 
by the fact that there was no correlation found between 
smoking and the level of 8-isoprostane and the fact that 
no smoking-related VOCs, like 2,4-dimethyl-1-heptene 
and 2,3-dimethylheptane (77), were found to discriminate 
between the patient and control groups in most of the 
studies. Furthermore, all studies reported that participants 
were restricted from smoking for at least 2 hours before 
EBC or breath collection (32), except in the study of Syslová 
et al. (69), ruling out potential acute effects of smoking on 
the breath composition. Nevertheless, there were some 
smoking-related VOCs found in some studies like benzene, 
2,5-dimethylfuran and toluene, but these VOCs were not 
found important discriminators between AEx subjects and 
MPM patients (31). We also need to take into account that 
smoking can induce CYP450, which can degrade the VOCs. 
Because of these reasons, the impact of smoking status 
on the results is expected to be minimal but the effect of 
smoking behaviour or VOC composition should be further 
investigated (31,75).
Fourthly,  the concentrations of exhaled breath 
biomarkers are sometimes difficult to interpret because of 
the inter-individual biological variability (large coefficients 
of variance) and different statistical methods used (32). For 
example, the production of inflammatory mediators can 
be determined by the individual differences in immune 
responses to the presence of asbestos fibres. This difference 
in immune response can influence the susceptibility to 
develop asbestos related diseases (70).
Fifthly, it seems difficult to match the patient and 
controls for age. MPM patients are significantly older than 
HC controls. The reasons for this mismatch are the latency 
period between first exposure to the causal agent and the 
diagnosis of this disease and the fact that older HC without 
significant comorbidities are hard to find (31). Furthermore, 
patients with asbestos-related disorders are older and 
consequently have, just like the HC, often concurrent 
respiratory and other pathologies (71). In general, there is 
a disagreement about the relevance of age and its effect on 
their metabolism and VOCs production (75).
Finally, it has to be mentioned that most studies are pilot 
studies with a cross-sectional design, MPM is a rather rare 
disease and the number of subjects included in the studies 
was therefore small (72-74). These small-scale studies 
show very promising results, but these outcomes need to 
be validated for larger studies. Hence, it is likely that the 
data was overfitted and results are overoptimistic. However, 
the different statistical analysis and validation seemed to be 
sufficient to obtain a clear separation between breath prints 
of the different groups (74) and encouraging VOCs were 
found important biomarkers for further investigation (72).
Nevertheless, the last publication of Lamote et al. (75) 
had already an increased number of subjects (n=330) among 
which 52 MPM patients were included. The results were 
in line with the previous studies and very satisfying, with 
high numbers of sensitivity and NPV. Unfortunately, it 
was not sufficient to discriminate between the different 
stages of MPM due to the low prevalence of sarcomatoid 
MPM (74). Most studies were pilot studies trying to 
identify VOCs specific for MPM (73). In these studies, a 
histological confirmation was needed, and studies were not 
blinded (31). A major drawback is that none of the studies 
could investigate the discrimination of asbestos-exposed 
individuals from early stage MPM patients, since the latter 
are hard to find. In order to overcome these drawbacks, we 
suggest future studies to adhere a prospective study design 
in which AEx subjects are screened and followed-up over 
time (73) and the investigator is blinded for the underlying 
pathology (31). This will also allow to study the use of a 
breath test to compare the different stages of MPM and to 
screen patients preferable in early stages of the disease, in 
hope to improve outcome (74). 
Conclusions
MPM is a very aggressive cancer mainly caused by a 
historical exposure to asbestos fibres and, although 
remaining a rare disease, its incidence is still increasing 
worldwide. It is a disease that is generally diagnosed at 
an advanced stage resulting in a high mortality rate. An 
early diagnosis is assumed to improve patients’ survival 
and urges the need for a good screening tool. Nowadays, 
the diagnosis is made with imaging and invasive methods 
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(CT scan, biopsy) due to a lack of non-invasive tools. As 
described in this review, the results of previous research 
into breath analysis are very promising. Breath analysis is a 
non-invasive and easy-to-use tool allowing a discrimination 
of at-risk groups from MPM patients with VOCs and 
markers like cyclohexane, 8-isoprostane, 8-OHdG and 
diethyl ether. The next step is the external validation of the 
breath compounds as biomarkers for disease and providing 
a biological link between VOCs of interest and MPM 
pathogenesis. These latter can be used to exclude MPM 
in individuals that are exposed to asbestos fibres thereby 
selecting patients for additional, more invasive diagnostic 
procedures. It is advised to perform blinded, prospective, 
case-control studies following up asbestos-exposed subjects 
over time. This will assess the clinical utility of a breath 
test and see if MPM can be detected in early stages, in 
comparison to other lung diseases.
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